Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S360000, C514S408000, C514S422000, C548S122000, C548S400000, C548S416000, C548S418000, C548S518000
Reexamination Certificate
active
07977368
ABSTRACT:
The invention provides compounds of Formula Iwherein A, Y, R1, R1a, R2, and R2aare as described in the specification. Compounds of Formula I are useful in treating and/or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of preparing compounds of Formula I, and methods of treating cognitive disorders, such as Alzheimer's disease.
REFERENCES:
patent: 6887898 (2005-05-01), Kim
patent: 7732609 (2010-06-01), Ye et al.
patent: 2002/0193399 (2002-12-01), Lin et al.
patent: 2005/0085506 (2005-04-01), Pissarnitski et al.
patent: 2006/0100233 (2006-05-01), Villa et al.
patent: 2006/0264380 (2006-11-01), Hellstrom et al.
patent: 2005/030776 (2005-04-01), None
patent: 2007/022502 (2007-02-01), None
patent: 2007/064914 (2007-06-01), None
patent: 2007/143523 (2007-12-01), None
Elser et al., Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1, Nature Cell Biol., 2(7), 428-434 (2000).
Li, Y.M. et al., “Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1,” Nature, 405(6787), 689-694 (2000).
Seiffert, D. et al., “Presenilin-1 and -2 ARe Molecular Targets for γ-Secretase Inhibitors,” J. Biol. Chem., 275(44), 34086-34091 (2000).
Konishi, J. et al., “γ-Secretase Inhibitor Prevents Notch3 Activation and Reduces Proliferation in Human Lung Cancers,” Cancer Res., 67(17), 8051-8057 (2007).
Miele, L. et al., “NOTCH Signaling as a Novel Cancer Therapeutic Target,” Curr. Cancer Drug Targets, 6(4), 313-323 (2006).
Buncel, E., “Chlorosulfates,” Chem. Rev., 70(3), 323-337 (1970).
McDermott, S.D. et al., “Synthesis and Reactions of Sulfamides. A Review,” Org. Prep. Proced. Int., 16(1), 49-77 (1984).
Chang, M.Y. et al., “Formal Synthesis of Epibatidine,” Heterocycles, 65(7), 1705-1711 (2005).
Knochel, P. et al., “Highly Functionalized Organomagnesium Reagents Prepared through Halogen-Metal Exchange,” Angew. Chem. Int. Ed., 42(36) 4302 (2003).
Liu et al., Synthesis of Enantiomerically Pure N-tert-Butanesulfinyl Imines (tert-Butanesulfinimines) by the Direct Condensation of tert-Butanesulfinamide with Aldehydes and Ketones, J. Org. Chem., 64, 1278-1284 (1999).
Davis et al., “Asymmetric Synthesis of cis-5-tert-Butylproline with Metal Carbenoid NH Insertion,” J. Org. Chem., 68, 5147-5152 (2003).
Hosseini et al., “Dipeptide Analogues Containing 4-Ethoxy-3-pyrrolin-2-ones,” Organic Letters, 8(10):2103-2106 (2006).
Fustero et al., “A Concise, Asymmetric Synthesis of Tetramic Acid Derivatives,” Organic Letters, 4(21):3651-3654 (2002).
Yoda et al., “An Efficient Asymmetric Functionalization to Highly Substituted Pyrrolidines,” Tetrahedron: Asymmerty, 6 (11):2669-2672 (1995).
Cogan et al., “Catalytic Asymmetric Oxidation of tert-Butyl Disulfide. Synthesis of tert-Butanesulfinamides, tert-Butyl Sulfoxides, and tert-Butanesulfinimines,” Journal of the American Chemical Society, 120(32) 8011-8019 (1998).
Davis et al., “Improved Synthesis of Enantiopure Sulfinimines (Thiooxime S-Oxides) fromp-Toluenesulfinamide and Aldehydes and Ketones,” J. Org. Chem., 64, 1403-1406 (1999).
David et al., “δ-Amino β-Keto Esters, a Designed Polyfunctionalized Chiral Building Block for Alkaloid Synthesis. Asymmetric Synthesis of (R)-(+)-2-Phenylpiperidine and (−)-SS20846A,” Organic Letters, 2(8):1041-1043 (2000).
Davis et al., “Asymmetric Synthesis of Substituted Prolines from δ-Amino β-Ketoesters. Methyl (2S,5R)-(+)-5-Phenylprrolidine-2-carboxylate,” Organic Letters, 4(9):1599-1602 (2002).
Guo et al., “Design, synthesis, an evaluation of tetrahydroisoquinoline and pyrrolidine sulfonamide carbamates as gamma-secretase inhibitors,” Bioorganic and Medicinal Chemistry Letters, 17, 3010-3013 (2007).
Bowers Simeon
Dressen Darren
Garofalo Albert W.
Hom Roy K.
Mattson Matthew N.
Elan Pharmaceuticals Inc.
Javanmard Sahar
McDonnell Boehnen & Hulbert & Berghoff LLP
Padmanabhan Sreeni
LandOfFree
Pyrazolopyrrolidines as inhibitors of gamma secretase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyrrolidines as inhibitors of gamma secretase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyrrolidines as inhibitors of gamma secretase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2724190